Standard BioTools Inc. Payments to Acquire Short-term Investments
Standard BioTools Inc. (LAB) reported Payments to Acquire Short-term Investments of $127.21 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2026-08-05
- Standard BioTools Inc. payments to acquire short-term investments for the quarter ending 2025-09-30 was $40.31M, a 48.73% decline year-over-year.
- Standard BioTools Inc. payments to acquire short-term investments for the quarter ending 2025-06-30 was $18.61M, a 75.13% decline year-over-year.
- Standard BioTools Inc. payments to acquire short-term investments for the quarter ending 2025-03-31 was $32.32M, a 55.83% decline year-over-year.
- Standard BioTools Inc. payments to acquire short-term investments for the quarter ending 2024-12-31 was $29.51M, a 24.42% decline year-over-year.
- Standard BioTools Inc. payments to acquire short-term investments for fiscal 2024 was $256.12M, a 169.89% increase from fiscal 2023.
- Standard BioTools Inc. payments to acquire short-term investments for fiscal 2023 was $94.90M, a 30.89% decline from fiscal 2022.
- Standard BioTools Inc. payments to acquire short-term investments for fiscal 2022 was $137.30M.
- Standard BioTools Inc. payments to acquire short-term investments for fiscal 2021 was $0.00.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $127.21M 10-Q · filed 2026-08-05 | |||
| 2025-09-30 | $40.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $58.92M derived: sum of 2 quarters · filed 2026-08-05 | $91.24M 10-Q · filed 2025-11-04 | $120.75M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $18.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $50.93M 10-Q · filed 2026-08-05 | $80.44M derived: sum of 3 quarters · filed 2026-08-05 | $159.06M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $32.32M 10-Q · filed 2025-05-06 | $61.83M derived: sum of 2 quarters · filed 2025-05-06 | $140.46M derived: sum of 3 quarters · filed 2025-11-04 | $215.26M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-12-31 | $29.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $108.14M derived: sum of 2 quarters · filed 2025-11-04 | $182.94M derived: sum of 3 quarters · filed 2025-11-04 | $256.12M 10-K · filed 2025-03-11 |
| 2024-09-30 | $78.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $153.44M derived: sum of 2 quarters · filed 2025-11-04 | $226.61M 10-Q · filed 2025-11-04 | $265.65M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $74.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-15 | $147.98M 10-Q · filed 2025-08-15 | $187.02M derived: sum of 3 quarters · filed 2025-08-15 | $236.04M derived: sum of 4 quarters · filed 2025-08-15 |
| 2024-03-31 | $73.18M 10-Q · filed 2025-05-06 | $112.22M derived: sum of 2 quarters · filed 2025-05-06 | $161.24M derived: sum of 3 quarters · filed 2025-05-06 | $161.24M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $39.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $88.06M derived: sum of 2 quarters · filed 2025-03-11 | $88.06M derived: sum of 3 quarters · filed 2025-03-11 | $94.90M 10-K · filed 2025-03-11 |
| 2023-09-30 | $49.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $49.02M derived: sum of 2 quarters · filed 2024-11-06 | $55.86M 10-Q · filed 2024-11-06 | $55.86M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $6.84M 10-Q · filed 2024-08-06 | $6.84M derived: sum of 3 quarters · filed 2025-03-11 | $6.84M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | $6.84M 10-Q · filed 2024-05-09 | $6.84M derived: sum of 2 quarters · filed 2025-03-11 | $6.84M derived: sum of 3 quarters · filed 2025-03-11 | $144.14M derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $0.00 derived: sum of 2 quarters · filed 2025-03-11 | $137.30M derived: sum of 3 quarters · filed 2025-03-11 | $137.30M 10-K · filed 2025-03-11 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $137.30M derived: sum of 2 quarters · filed 2023-11-07 | $137.30M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $137.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $137.30M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |